A randomised trial of the pharmacodynamic and pharmacokinetic effects of ticagrelor compared with clopidogrel in Hispanic patients with stable coronary artery disease

Journal of Thrombosis and Thrombolysis

Volumn 39, Issue 1, 2015, Pages 8-14

  Price, Matthew J ^a   Clavijo, Leonardo ^b   Angiolillo, Dominick J ^c   Carlson, Glenn ^d   Caplan, Richard ^d   Teng, Renli ^d   Maya, Juan ^d  

^a University of Southern California ^*  (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c UNIVERSITY OF FLORIDA HEALTH JACKSONVILLE   (United States)

^d ASTRAZENECA   (United Kingdom)

Author keywords

Clopidogrel; Coronary artery disease; Hispanic; Platelet reactivity; Ticagrelor

Indexed keywords

CLOPIDOGREL; TICAGRELOR; ADENOSINE; PURINERGIC P2Y RECEPTOR ANTAGONIST; TICLOPIDINE;

ADULT; AGED; ARTICLE; BLEEDING; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; EVENING DOSAGE; FEMALE; HISPANIC; HUMAN; LOADING DRUG DOSE; MAINTENANCE DRUG DOSE; MALE; MORNING DOSAGE; MULTICENTER STUDY; OPEN STUDY; PHARMACODYNAMICS; PLATELET REACTIVITY; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTE FUNCTION ANALYZER; UNSPECIFIED SIDE EFFECT; ANALOGS AND DERIVATIVES; BLOOD; CLINICAL TRIAL; COMPARATIVE STUDY; DRUG EFFECTS; METABOLISM; MIDDLE AGED; THROMBOCYTE; THROMBOCYTE ACTIVATION;

ADENOSINE; AGED; BLOOD PLATELETS; CORONARY ARTERY DISEASE; HISPANIC AMERICANS; HUMANS; MIDDLE AGED; PLATELET ACTIVATION; PURINERGIC P2Y RECEPTOR ANTAGONISTS; TICLOPIDINE;

EID: 84921377573     PISSN: 09295305     EISSN: 1573742X     Source Type: Journal    
DOI: 10.1007/s11239-014-1135-9     Document Type: Article

References (8)

1. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Borden WB, Bravata DM, Dai S, Ford ES, Fox CS, Franco S, Fullerton HJ, Gillespie C, Hailpern SM, Heit JA, Howard VJ, Huffman MD, Kissela BM, Kittner SJ, Lackland DT, Lichtman JH, Lisabeth LD, Magid D, Marcus GM, Marelli A, Matchar DB, McGuire DK, Mohler ER, Moy CS, Mussolino ME, Nichol G, Paynter NP, Schreiner PJ, Sorlie PD, Stein J, Turan TN, Virani SS, Wong ND, Woo D, Turner MB, American Heart Asssociation Statistics Committee and Stroke Statistics Subcommittee (2013) Heart disease and stroke statistics–2013 update: a report from the American Heart Association. Circulation 127:e6–e245
2. Conway PH, Clancy C (2009) Comparative-effectiveness research–implications of the Federal Coordinating Council’s Report. N Engl J Med 361:328–330
3. Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, Horrow J, Husted S, James S, Katus H, Mahaffey KW, Scirica BM, Skene A, Steg PG, Storey RF, Harrington RA, PLATO Investigators, Freij A, Thorsén M (2009) Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 361:1045–1057
4. Price MJ (2009) Bedside evaluation of thienopyridine antiplatelet therapy. Circulation 119:2625–2632
5. Gurbel PA, Bliden KP, Butler K, Tantry US, Gesheff T, Wei C, Teng R, Antonino MJ, Patil SB, Karunakaran A, Kereiakes DJ, Parris C, Purdy D, Wilson V, Ledley GS, Storey RF (2009) Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study. Circulation 120:2577–2585
6. Bradley EH, Herrin J, Wang Y, McNamara RL, Webster TR, Magid DJ, Blaney M, Peterson ED, Canto JG, Pollack CV Jr, Krumholz HM (2004) Racial and ethnic differences in time to acute reperfusion therapy for patients hospitalized with myocardial infarction. JAMA 292:1563–1572
7. Sabatine MS, Blake GJ, Drazner MH, Morrow DA, Scirica BM, Murphy SA, McCabe CH, Weintraub WS, Gibson WS, Cannon CP (2005) Influence of race on death and ischemic complications in patients with non-ST-elevation acute coronary syndromes despite modern, protocol-guided treatment. Circulation 111:1217–1224
8. Hurley LP, Dickinson LM, Estacio RO, Steiner JF, Havranek EP (2010) Prediction of cardiovascular death in racial/ethnic minorities using Framingham risk factors. Circ Cardiovasc Qual Outcomes 3:181–187